25-hydroxy Vitamin D3

Confirm delete?

25-hydroxy Vitamin D₃

Zoom

Cat No: 9000683

Biochemicals - Lipids

Deficiency of vitamin D leads to abnormal calcium and phosphorus metabolism, contributing to deficiencies in bone formation, neuromuscular function, and inflammatory response. 25-hydroxy Vitamin D3 is an intermediate in the pathway leading to the produ...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

4-[(2Z)-2-[(5S)-5-hydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-?,?,?,7a-tetramethyl-(?R,1R,3aS,4E,7aR)-1H-indene-1-pentanol

Correlated keywords:

25631-40-7 calcidiol calcifediol calderol dedrogyl didrogyl hidroferol Hy-D Ro 8-8892 Rovimix Hy-D U 32070E U-32070E U32070E 25-OH cholecalciferol 25-OH vitamin D3 25-hydroxyvitamin D3 phosphorus metabolism neuromuscular inflammatory intermediates receptors livers kidneys plasma serum

Product Overview:
Deficiency of vitamin D leads to abnormal calcium and phosphorus metabolism, contributing to deficiencies in bone formation, neuromuscular function, and inflammatory response. 25-hydroxy Vitamin D3 is an intermediate in the pathway leading to the production of 1,25-dihydroxy vitamin D3, the most receptor-active form of vitamin D. 25-hydroxy Vitamin D3, produced in the liver from vitamin D3, is metabolized in the kidney to 1,25-dihydroxy vitamin D3. Plasma or serum levels of 25-hydroxy vitamin D3 are commonly used as an indicator of an individual’s vitamin D status.{19429}

Size	1 mg
Shipping	dry ice
CAS Number	19356-17-3
Molecular Formula	C₂₇H₄₄O₂
SMILES	[H][C@]([C@]1(C)CCC/2)(CC[C@]1([H])[C@H](C)CCCC(C)(O)C)C2=C\C=C3C[C@@H](O)CCC\3=C
Molecular Weight	400,6
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2936.29
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.